Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 8
Submit an article Journal homepage
148
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting

Sherry Mori-Vogt Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The Ohio State University, The Martha Morehouse Medical Plaza, 2050 Kenny Road, Suite 377 Tower Building, Columbus, OH 43221, USA. [email protected]; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The Ohio State University, The Martha Morehouse Medical Plaza, 2050 Kenny Road, Suite 377 Tower Building, Columbus, OH 43221, USA. [email protected]
&
Marlo Blazer Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The OH State University, The Martha Morehouse Medical Plaza, 2050 Kenny Road, Suite 824 Tower Building, Columbus, OH 43221, USA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The OH State University, The Martha Morehouse Medical Plaza, 2050 Kenny Road, Suite 824 Tower Building, Columbus, OH 43221, USA
Pages 919-936 | Published online: 10 Jan 2014

References

  • Coates A, Abraham S, Kaye SB et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 19(2), 203–208 (1983).
  • Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J. Clin. Oncol. 7(8), 1142–1149 (1989).
  • Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support. Care Cancer 5(4), 307–313 (1997).
  • Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 12(5), 341–347 (2006).
  • Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N. Engl. J. Med. 328(24), 1790–1796 (1993).
  • Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol. Rev. 5(2), 193–230 (1953).
  • Minami M, Endo T, Hirafuji M et al. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol. Ther. 99(2), 149–165 (2003).
  • Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338(8765), 483–487 (1991).
  • Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systemic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. 23(6), 1289–1294 (2005).
  • Gralla RJ, de Wit R, Herrstedt J et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5-HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 104(4), 864–868 (2005).
  • Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized Phase III trial. J. Support. Oncol. 9(5), 188–195 (2011).
  • Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23(12), 2822–2830 (2005).
  • Havorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 52(5), 639–648 (1996).
  • Wong EH, Clark R, Leung E et al. The interaction of RS25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol. 114(4), 851–859 (1995).
  • Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14(10), 1570–1577 (2003).
  • Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98(11), 2473–2482 (2003).
  • Grunberg S, Chua D, Maru A et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. J. Clin. Oncol. 29(11), 1495–1501 (2011).
  • Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12), 3090–3098 (2003).
  • Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst. Rev. (1), CD006272 (2010).
  • Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative Phase III trial. Lancet Oncol. 10(2), 115–124 (2009).
  • Piraccini G. Pharmacokinetic features of a novel 5-HT3 receptor antagonist: palonosetron (RS-25259-197). Presented at: 37th ASCO Annual Meeting. San Francisco, CA, USA, 15–21 May 2001.
  • Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT(3) RA selection with triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 481–488 (2011).
  • Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support. Care Cancer 19(6), 823–832 (2011).
  • Roscoe JA, Heckler CE, Morrow GR et al. Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J. Clin. Oncol. 30(27), 3389–3395 (2012).
  • Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T; Palonosetron 04-06 Study Group. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for prevention postoperative nausea and vomiting. Anesth. Analg. 107(2), 445–451 (2008).
  • Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur. J. Pharmacol. 684(1–3), 1–7 (2012).
  • Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol. 15(2), 330–337 (2004).
  • Addelman M, Erlichman C, Fine S, Warr D, Murray C. Phase I/II of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J. Clin. Oncol. 8(2), 337–341 (1990).
  • Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. 29(2), 95–109 (1995).
  • Lippert CL, Dimmitt DC, Martin L, Cramer MB, Plezia P, Hahne WF. Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. Am. J. Ther. 6(3), 129–135 (1999).
  • Kees F, Farber L, Bucher M, Mair G, Morike K, Grobecker H. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br. J. Clin. Pharmacol. 52(6), 705–707 (2001).
  • Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth. Analg. 107(2), 469–478 (2008).
  • Rojas C, Thomas AG, Alt J et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol. 626(2–3), 193–199 (2010).
  • Rojas C, Li Y, Zhang J et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J. Pharmacol. Exp. Ther. 335(2), 362–368 (2010).
  • Eglen RM, Lee CH, Smith WL et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br. J. Pharmacol. 114(4), 860–866 (1995).
  • Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol. 44(5), 520–531 (2004).
  • Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm. Drug Dispos. 25(8), 329–337 (2004).
  • Shah A, DeGroot T, Apseloff G. Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects. J. Clin. Pharmacol. 46(10), 1139–1145 (2006).
  • Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a Phase 3 trial. Support. Care Cancer 21(5), 1453–1460 (2013).
  • Maemondo M, Masuda N, Sekine I et al. A Phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann. Oncol. 20(11), 1860–1866 (2009).
  • Segawa Y, Aogi K, Inoue K et al. A Phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann. Oncol. 20(11), 1874–1880 (2009).
  • Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J. Support. Oncol. 4(9), 467–471 (2006).
  • Di Renzo N, Montanini A, Mannina D et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a Phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support. Care Cancer 19(10), 1505–1510 (2011).
  • Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J. Support. Oncol. 4(8), 403–408 (2006).
  • Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support. Care Cancer 20(3), 653–656 (2012).
  • Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support. Care Cancer 17(5), 589–594 (2009).
  • Longo F, Mansueto G, Lapadula V et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int. J. Clin. Pract. 66(8), 753–757 (2012).
  • Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9), 2080–2087 (2008).
  • Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17(9), 1441–1449 (2006).
  • Aogi K, Sakai H, Yoshizawa H et al. A Phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support. Care Cancer 20(7), 1507–1514 (2012).
  • Aapro M, Fabi A, Nole F et al. Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann. Oncol. 21(5), 1083–1088 (2010).
  • Celio L, Frustaci S, Denaro A et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, Phase III trial. Support. Care Cancer 19(8), 1217–1225 (2011).
  • Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two Phase III trials. Support. Care Cancer 21(2), 565–573 (2013).
  • Musso M, Scalone R, Crescimanno A et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant. 45(1), 123–127 (2010).
  • Giralt SA, Mangan KF, Maziarz RT et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann. Oncol. 22(4), 939–946 (2011).
  • Rzepecki P, Pielichowki W, Oborska S, Barzal J, Mlot B. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. Transplant. Proc. 41(8), 3247–3249 (2009).
  • Pielichowski W, Barzal J, Gawronski K et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous stem cell transplantation. Transplant. Proc. 43(8), 3107–3110 (2011).
  • Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support. Care Cancer 15(11), 1293–1300 (2007).
  • Gonullu G, Demircan S, Demirag MK, Erdem D, Yucel I. Electrocardiographic findings of palonosetron in cancer patients. Support. Care Cancer 20(7), 1435–1439 (2012).
  • Dogan U, Yavas G, Tekinalp M, Yavas C, Ata OY, Ozdemir K. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. Eur. Rev. Med. Pharmacol. Sci. 16(4), 462–468 (2012).
  • Yavas C, Dogan U, Yavas G, Araz M, Ata OY. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study. Support. Care Cancer 20(10), 2343–2347 (2012).
  • Hu WP, You XH, Guan BC, Ru LQ, Chen JG, Li ZW. Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci. Lett. 365(2), 147–152 (2004).
  • Minami M, Endo T, Yocota H et al. Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur. J. Pharmacol. 428(2), 215–220 (2001).
  • Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated response in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur. J. Pharmacol. 689(1–3), 25–30 (2012).
  • Yu Z, Liu W, Wang L et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in Chinese cancer patients: a Phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support. Care Cancer 17(1), 99–102 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.